Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
taxane + carboplatin + trastuzumab + pertuzumab
- Development stage
- Unknown
- Lead developer
- Guangdong Provincial People's Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A neoadjuvant chemotherapy and targeted therapy regimen consisting of a taxane (docetaxel, paclitaxel, or nab-paclitaxel), carboplatin, trastuzumab, and pertuzumab. This combination, commonly referred to as TCHP or TCbHP, is being evaluated in the Phase III neoCARHP trial (NCT04858529) led by Guangdong Provincial People's Hospital for the treatment of HER2-positive early breast cancer. The regimen utilizes dual HER2 blockade via the monoclonal antibodies trastuzumab and pertuzumab, which bind to different domains of the HER2 receptor to inhibit downstream signaling and dimerization. This is combined with the cytotoxic effects of carboplatin, a platinum-based DNA alkylator, and a taxane, which stabilizes microtubules to prevent cell division. The trial compares this four-drug regimen against a de-escalated three-drug regimen (THP) to assess efficacy and toxicity.
- Other names
- taxane + carboplatin + trastuzumab + pertuzumab-Guangdong Provincial People's Hospital-breast cancer (HER2-positive)neoCARHP regimeninvestigator-selected taxane/carboplatin/trastuzumab/pertuzumab
02
Targets
DNAHER2 ECD subdomain II (Human epidermal growth factor receptor 2 dimerization interface)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on taxane + carboplatin + trastuzumab + pertuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on taxane + carboplatin + trastuzumab + pertuzumab.